Litcius/Paper detail

The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial.

Shaohui Chen, Jin Wang, Xiaohan Xu, Yuguang Huang, Shanfu Xue, Anshi Wu, Xiaoju Jin, Qiang Wang, Jianrui Lyu, Sheng Wang, Yujuan Li, Yonghao Yu, AI Deng-bin, Ailin Luo, Su Min, Lin Li, Xiaohua Zou, Jin Liu, Peilin Lv, Xiaoqin Chai, Xude Sun, Zhibin Zhao, Jiaqiang Zhang

2020PubMed162 citationsOpen Access PDF

Abstract

<0.001) were less frequent in remimazolam group compared with propofol group. In conclusion, remimazolam tosylate is non-inferior in sedation efficacy while safer than propofol in patients undergoing colonoscopy.

Topics & Concepts

MedicinePropofolSedationColonoscopyAnesthesiaAdverse effectRandomized controlled trialSurgeryInternal medicineColorectal cancerCancerAnesthesia and Sedative AgentsAnesthesia and Neurotoxicity ResearchIntensive Care Unit Cognitive Disorders
The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. | Litcius